167 related articles for article (PubMed ID: 17593982)
1. Alemtuzumab in chronic lymphocytic leukemia.
Fraser G; Smith CA; Imrie K; Meyer R;
Curr Oncol; 2007 Jun; 14(3):96-109. PubMed ID: 17593982
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
Reece D; Imrie K; Stevens A; Smith CA;
Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
5. Management of single brain metastasis: a practice guideline.
Mintz A; Perry J; Spithoff K; Chambers A; Laperriere N
Curr Oncol; 2007 Aug; 14(4):131-43. PubMed ID: 17710205
[TBL] [Abstract][Full Text] [Related]
6. Single-agent interleukin-2 in the treatment of metastatic melanoma.
Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide for the treatment of metastatic melanoma.
Quirbt I; Verma S; Petrella T; Bak K; Charette M;
Curr Oncol; 2007 Feb; 14(1):27-33. PubMed ID: 17576461
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M
Curr Oncol; 2007 Aug; 14(4):144-8. PubMed ID: 17710206
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab for patients with chronic lymphocytic leukaemia.
Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
14. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline.
Verma S; Petrella T; Hamm C; Bak K; Charette M;
Curr Oncol; 2008 Apr; 15(2):85-9. PubMed ID: 18454183
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
16. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging treatments for chronic lymphocytic leukaemia.
Robak T; Jamroziak K; Robak P
Drugs; 2009; 69(17):2415-49. PubMed ID: 19911856
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).
Montillo M; Ricci F; Miqueleiz S; Tedeschi A; Morra E
Biologics; 2008 Mar; 2(1):41-52. PubMed ID: 19707426
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Hoyle M; Crathorne L; Garside R; Hyde C
Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]